<DOC>
	<DOCNO>NCT00772629</DOCNO>
	<brief_summary>This study design generate data assessment Meningococcal Polysaccharide Diphtheria Toxoid Conjugate vaccine ( Menactra® ) give adult age 18 55 year . Primary Objective : To describe antibody response serogroup prior , 4 6 week follow , administration one dose investigational Meningococcal Polysaccharide Diphtheria Toxoid Conjugate vaccine ( Menactra® ) , measure serum bactericidal activity use baby rabbit complement ( SBA BR ) participant two study group . Secondary Objective : To collect reference serum development refinement laboratory assay measurement antibody responses serogroups Y W 135 .</brief_summary>
	<brief_title>Antibody Responses Following Meningococcal Tetravalent ( A , C , Y , W-135 ) Conjugate Vaccination Healthy Adults</brief_title>
	<detailed_description>Enrollment terminate planned sample size achieve principal investigator Sponsor decide sufficient serum obtain meet secondary objective study . There safety concern involve decision stop enrollment . Subjects enrol time complete study per protocol , last subject last visit 29 April 2004 .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Inclusion Criteria : Participant least 18 year age yet 56 year age time vaccination . Participant receive either unconjugated meningococcal polysaccharide ( serogroups A C , A , C , Y , W 135 ) vaccine least one year prior enrollment ( assignment Group 2 ) prior history meningococcal vaccination ( assignment Group 1 ) . Participant sign Ethics Committeeapproved inform consent form . Exclusion Criteria : Serious chronic disease ( i.e. , cardiac , renal , neurologic , metabolic , rheumatologic , psychiatric , etc . ) Known suspect impairment immunologic function Acute medical illness without fever within last 72 hour oral temperature ≥ 38°C time inclusion History document invasive meningococcal disease Administration immune globulin blood product within last three month , injected oral corticosteroid immunomodulatory therapy within six week study vaccine . Individuals taper dose schedule oral steroid last &lt; 7 day allow included trial long receive one course within last two week prior enrollment . Antibiotic therapy within 72 hour prior vaccination 72 hour prior draw blood sample Visit 2 Received unconjugated meningococcal polysaccharide ( serogroups A C , A , C , Y , W 135 ) vaccine within oneyear period prior enrollment conjugate meningococcal vaccine time prior enrollment Received vaccine 28day period prior enrollment , schedule receive vaccination participation study Suspected known hypersensitivity vaccine component Unavailable entire study period , unable attend schedule visit comply study procedure Enrolled another clinical trial In female , pregnancy confirm positive urine test result In female , current breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Menactra®</keyword>
	<keyword>Meningitis</keyword>
	<keyword>Meningococcemia</keyword>
	<keyword>Neisseria meningitidis</keyword>
</DOC>